Banco Santander S.A. Has $1.81 Million Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Banco Santander S.A. reduced its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 13.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 120,000 shares of the company’s stock after selling 18,373 shares during the period. Banco Santander S.A.’s holdings in Pacira BioSciences were worth $1,806,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its holdings in shares of Pacira BioSciences by 1,780.2% in the 1st quarter. Jane Street Group LLC now owns 187,531 shares of the company’s stock valued at $5,480,000 after buying an additional 177,557 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Pacira BioSciences by 12.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock valued at $52,300,000 after buying an additional 198,936 shares during the last quarter. Legato Capital Management LLC boosted its holdings in shares of Pacira BioSciences by 74.0% in the 2nd quarter. Legato Capital Management LLC now owns 52,913 shares of the company’s stock valued at $1,514,000 after buying an additional 22,497 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in shares of Pacira BioSciences in the 2nd quarter valued at approximately $2,726,000. Finally, Pacer Advisors Inc. boosted its holdings in shares of Pacira BioSciences by 129.4% in the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock valued at $74,681,000 after buying an additional 2,799,434 shares during the last quarter. 99.73% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on PCRX shares. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Pacira BioSciences in a report on Friday, November 8th. Truist Financial cut Pacira BioSciences from a “buy” rating to a “sell” rating and dropped their price target for the company from $30.00 to $8.00 in a research note on Tuesday, August 13th. StockNews.com cut Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 12th. Jefferies Financial Group increased their price target on Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Finally, HC Wainwright dropped their price target on Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Stock Up 1.0 %

Shares of NASDAQ:PCRX opened at $17.55 on Friday. The firm has a 50 day moving average of $16.12 and a 200-day moving average of $20.40. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.